Do GLP-1 Drugs Cause Psychiatric Problems? A Real-World Study Says Mostly No | Research

The takeaway

GLP-1 drugs did not increase the risk of most psychiatric disorders compared to other diabetes medications, though a modest link to anxiety was found.

No increased psychiatric risk for most disorders
Compared to SGLT2 inhibitors and DPP-4 inhibitors, GLP-1 drugs showed no association with increased risk of most psychiatric conditions in adults with type 2 diabetes, though anxiety showed a modest association.

What the researchers found

GLP-1 receptor agonists were not associated with increased risk of most psychiatric disorders compared to SGLT2 inhibitors or DPP-4 inhibitors in adults with type 2 diabetes. However, a modest association with anxiety disorder was observed. The study used target trial emulation — a rigorous real-world evidence method that mimics the design of a randomized clinical trial using observational data — to compare psychiatric outcomes across these three diabetes drug classes.

Why it matters

Reports of suicidal thoughts and other psychiatric symptoms in GLP-1 drug users have prompted FDA investigations and widespread concern. This study provides reassurance that GLP-1 drugs do not appear to increase the risk of most psychiatric conditions compared to other diabetes medications, though the anxiety signal warrants attention. This is particularly important given the millions of people now taking these drugs for diabetes and obesity.

How the study worked

Target trial emulation using real-world data — a method that designs an observational study to mimic a randomized controlled trial. Researchers compared psychiatric outcomes in adults with type 2 diabetes who initiated GLP-1 receptor agonists versus those who started SGLT2 inhibitors or DPP-4 inhibitors. The study assessed risk of various psychiatric disorders including anxiety.

Who was studied

Adults with type 2 diabetes initiating GLP-1 receptor agonists, SGLT2 inhibitors, or DPP-4 inhibitors

What this study cannot tell us

As an observational study (even with target trial emulation), residual confounding cannot be completely ruled out. The abstract is brief and does not detail the specific psychiatric outcomes assessed beyond anxiety, the exact population size, follow-up duration, or effect sizes. The study population was limited to adults with type 2 diabetes, so findings may not generalize to people taking GLP-1 drugs solely for obesity.

How to read the evidence

This is a moderate-strength observational study using target trial emulation, a rigorous method that mimics randomized trial design with real-world data. While stronger than a simple retrospective analysis, it cannot fully eliminate confounding the way a true randomized trial would.

When this study was published

Published in 2026, this is a very current study directly addressing one of the most pressing safety questions about GLP-1 drugs — their potential psychiatric effects.

The bigger picture

The FDA has been investigating reports linking GLP-1 drugs to suicidal thoughts and other psychiatric symptoms. This study is part of a growing body of real-world evidence examining this question. The largely reassuring results — no increased risk for most psychiatric conditions — help calm concerns, but the anxiety signal adds nuance to the safety picture. As GLP-1 drug use continues to expand, psychiatric safety monitoring remains important.

Questions still open

What is driving the modest association between GLP-1 drugs and anxiety — is it pharmacological or related to the experience of rapid weight/appetite changes?
Would these findings hold in people taking GLP-1 drugs for obesity rather than diabetes?
Are specific GLP-1 drugs (semaglutide vs. liraglutide) differentially associated with psychiatric outcomes?

Common questions

Do GLP-1 drugs like Ozempic cause depression or suicidal thoughts?

This study found no increased risk of most psychiatric disorders, including depression, when comparing GLP-1 drug users to people on other diabetes medications. However, a modest association with anxiety was observed. The FDA continues monitoring psychiatric safety signals, but this real-world evidence is largely reassuring.

What is a target trial emulation and why does it matter?

It's a research method that uses real-world patient data but analyzes it as if it were a randomized clinical trial — assigning a 'start date,' defining eligibility criteria, and following patients forward in time. This makes the results more reliable than typical observational studies, though not quite as strong as an actual randomized trial.

Read the original research

Association of GLP-1 receptor agonist use with psychiatric outcomes in adults with type 2 diabetes: a target trial emulation.

Diabetes research and clinical practice, 231, 113038

View on PubMed ↗Publisher’s paper ↗

Citation

Tang, Huilin; Lu, Yiwen; Zhang, Bingyu; Zhang, Dazheng; Zhou, Ting; Chen, Jiajie; Lu, Ying; Lyu, Tianchu; Zheng, Kai; Chen, Yong. (2026). Association of GLP-1 receptor agonist use with psychiatric outcomes in adults with type 2 diabetes: a target trial emulation.. Diabetes research and clinical practice, 231, 113038. https://doi.org/10.1016/j.diabres.2025.113038